MedTrace Logo

Renal Resistive Index as a Predictor of Acute Kidney Injury and Evaluation of Fluid Administration in Sepsis

NCT06009445 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-08-24

No results posted yet for this study

Summary

We aim from this study to investigate the role of renal resistance index (RRI) in evaluation of Acute kidney injury development and fluid administration in sepsis patients considering the change in RRI values over 7 days from admission as a predictor of AKI development

Conditions

Interventions

DIAGNOSTIC_TEST

Renal resistive index

The calculation formula for Renal resistive index (RRI) as follows : (systolic peak flow velocity \_ diastolic minimum flow velocity )/systolic peak flow velocity . will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney. The median value of each section will be used and the 3 median values of each kidney will be averaged.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Safinaz A Aboelfetoh, MBBCh · Anesthesiology, Faculty of Medicine, Tanta University, Egypt.

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06009445 on ClinicalTrials.gov